GoKawiilMerck-Moderna mRNA vaccine cuts melanoma recurrence risk by 42% in Phase 3 trial
Merck and Moderna announced Phase 3 results for a personalized mRNA vaccine, Intismeran Autogene, given alongside the immunotherapy drug Pembrolizumab to 1,137 high-risk melanoma patients after tumor removal surgery. Over an average 24.6-month follow-up, the combination reduced recurrence or death risk by 42% and metastasis risk by 38% compared with Pembrolizumab alone, with 82.2% of combination-treatment patients remaining recurrence-free versus 70% on Pembrolizumab alone.
GoKawiil's interpretation of the reporting above, not reported fact.
Researchers including principal investigator Georgina Long and independent oncologist Eva Muñoz Couselo describe the findings as a major advance for personalized cancer medicine, suggesting mRNA technology could extend beyond infectious disease into individualized cancer treatment. If confirmed in further trials and regulatory review, this approach could reshape standard care for high-risk melanoma patients after surgery, though longer-term survival data and regulatory approval are still needed.
- Combination of mRNA vaccine Intismeran Autogene with Pembrolizumab cut melanoma recurrence/death risk by 42% versus Pembrolizumab alone.
- Trial involved 1,137 high-risk melanoma patients post-surgery, followed for an average of 24.6 months.
- Experts call the results a potential foundational shift toward personalized cancer treatment, pending further validation.
ISDIN Eryfotona Mineral SPF 50+ Sunscreen — While this vaccine breakthrough targets melanoma treatment after diagnosis, daily sun protection remains the best first line of defense against skin cancer. A high-SPF mineral sunscreen helps reduce UV damage that can lead to melanoma in the first place, making it a smart everyday companion to medical advances like this one.
See ISDIN Eryfotona Mineral SPF 50+ Sunscreen on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.Source: wired.com — Fernanda González, 2026-10-24
Published there as: “New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.